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Virginie Beauséjour Ladouceur, MDT he last 2 decades have borne witness toa rapid and vigorous expansion of ourunderstanding of the genetic basis underly-
ing many cardiovascular diseases. As fellows-in-
training, this marks an exciting time with a rapid
tempo of discovery that keeps us in constant motion,
which challenges us to keep up with current develop-
ments to provide optimal cardiovascular care to our
patients. Since the discovery in 1990 that a mutation
in the b cardiac myosin heavy chain, a component
of the sarcomere, caused familial hypertrophic car-
diomyopathy (1,2), investigators in the ﬁeld of cardio-
vascular genetics have developed an increasingly
complex understanding of the pathophysiologic basis
of inherited cardiac diseases (3). Genetic testing for
these heritable diseases has rapidly advanced from
basic scientiﬁc discovery to clinical application, and
commercially targeted gene testing and comprehen-
sive disease panels have entered mainstream car-
diology practice in the past several years (4).
Clinical screening tools for whole-exome or -genome
sequencing are becoming exponentially more afford-
able and accessible and are now entering the clinical
world. However, technical advances in deoxyribonu-
cleic acid sequencing methodology have outpaced
our ability to conﬁdently understand the clinical sig-
niﬁcance of these ﬁndings. Increasingly, both adult
and pediatric cardiologists are being called upon to
serve as interpreters of the genetic language re-
levant to cardiovascular disease. This will necessitate
focused training pathways for fellows to acquire the
ﬂuency to understand the rapidly expanding land-
scape of cardiovascular genetics and the requisite
expertise to accurately recognize the cardiac and
extracardiac phenotypes of inherited cardiovascular
disorders.From the Department of Pediatric Cardiology, Boston Children’s Hospital,
Harvard Medical School, Boston, Massachusetts; and Adult/Pediatric
Cardiovascular Genetics, Boston Children’s Hospital and Brigham and
Women’s Hospital, Boston, Massachusetts.We will brieﬂy consider 5 likely referrals to a car-
diovascular medicine specialist. First, an 18-year-old
competitive swimmer presents for evaluation of
exertional syncope in the context of a family history
of sudden cardiac death. He is found to have a
borderline QT interval, with a QTc of 480 ms on the
electrocardiogram. How can genetic testing help with
the care of this patient? Second, a 34-year-old woman
with pre-hypertension is found to have mode-
rate concentric left ventricular hypertrophy on a
screening echocardiogram performed for evaluation
of a murmur. Should this patient have genetic testing
for hypertrophic cardiomyopathy–associated muta-
tions, including b-myosin heavy chain gene (MYH7)
and myosin binding protein C (MYBPC3)? Third, a
55-year-old man with normal low-density lipoprotein
cholesterol and Framingham risk score is referred for
recommendations regarding primary prevention of
atherosclerotic cardiovascular disease. His family
history is notable because his father had a myocardial
infarction at 50 years of age. The patient has read
about testing for genetic variants at the 9p21 locus
and asks if he “should get this test?” Fourth, as part of
an unrelated research study, a 45-year-old woman
undergoes whole-exome sequencing that reveals a
variant in the titin (TTN) gene, which has been asso-
ciated with nonischemic dilated cardiomyopathy. She
has no clinical phenotype and is not aware of family
members with cardiac disease. How should she be
counseled regarding this ﬁnding? Finally, a 46-year-
old patient is referred for implantable cardioverter-
deﬁbrillator (ICD) extraction after device infection.
Her ICD was placed for primary prevention in the
setting of a syncopal episode and commercial genetic
testing, revealing a variant in SCN5A (1 of the genes
involved in Brugada syndrome and long QT syn-
drome), which at the time, was thought to be likely
pathogenic, but has since been downgraded to a
variant of unknown signiﬁcance. Was initial ICD
implantation appropriate, and should it be replaced?
Many cardiovascular trainees might feel under-
prepared to care for these patients. Indeed, despite
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857the rapid expansion in cardiovascular genetics,
trainees generally have limited exposure to car-
diovascular genetics during their fellowships.
Although such patients are increasingly, and appro-
priately, referred to specialized clinics, a funda-
mental understanding of the management of such
patients is incumbent on all cardiologists. Deter-
mining the optimal elements of training during gen-
eral adult or pediatric cardiology fellowship as well as
deﬁning the structure and role of novel advanced
training pathways are both key to ﬁlling this gap.
As illustrated, the ﬁeld of cardiovascular genetics
encompasses a wide variety of inherited cardiac
conditions from monogenic diseases, such as chan-
nelopathies (long QT syndrome, Brugada syndrome,
and catecholaminergic polymorphic ventricular
tachycardia), cardiomyopathies (dilated, hypertro-
phic, and arrhythmogenic), connective tissue dis-
eases (Marfan syndrome and Loeys-Dietz syndrome),
and familial dyslipidemias, to those with a more
complex inheritance pattern, such as certain forms of
congenital heart disease and perhaps even coronary
artery disease. Additionally, the pleiotropy of many
genes and increasingly recognized overlap syndromes
add to the clinical complexity. With genetic testing
for these conditions and others becoming more
available, and even publicly accessible in some cases
(5), cardiologists will be increasingly looked upon to
help navigate these tests, ideally including pre-test
counseling to ensure that expectations regarding the
beneﬁts and limitations of testing are appropriate.
Cardiologists with knowledge of genotype and
phenotype are also needed to accurately interpret
the results of genetic testing in the context of the
patient and family under their care. As genetic testing
advances and next-generation sequencing become
more accessible, policy makers may seek out cardi-
ologists to help chart a course for responsible use of
these technologies (6).
Current cardiovascular genetics specialists have
evolved from various backgrounds, including elec-
trophysiology, heart failure, advanced imaging, and
preventive cardiology. In the absence of precedent
or standardization, such specialists have generally
deﬁned their own learning pathways, curricula, and
clinical exposures. Clearly, there is an evolving need to
train specialists in cardiovascular genetics, and such
programs are needed and sought after by fellows-in-
training. To facilitate this training, 2 alternate, but
not exclusive, pathways could be chosen: 1) continue
with the current approach of adding supplemental
cardiovascular genetics training to 1 of the traditional
cardiovascular subspecialties; or 2) deﬁne this as a
brand-new training opportunity.The core elements of either trajectory would
include: 1) development of expertise in thorough
clinical phenotyping of probands and family mem-
bers, using the family as the unit of care; 2) devel-
opment of an approach to the (often gray) indications
for genetic testing, including selection of appropriate
tests (targeted sequencing, disease-panels, whole
genome sequencing, and so on) and optimal testing
strategy (selection of the family proband, directing
cascade screening); 3) proﬁciency in interpreting
genetic testing results, including the technical as-
pects of variant classiﬁcation, and integrating results
in the context of a patient’s and family’s phenotype;
4) proﬁciency in genetic counseling; 5) knowledge of
appropriate management of various common car-
diovascular disorders with a genetic basis; and
6) research training, including the ethical, social, and
legal implications of genetic investigation, genetic
testing, and familial disease.
Examples of important experiences for the trainee,
which could accomplish these learning objectives,
include participation in an outpatient family clinic
focused on inherited cardiovascular disorders and
associated molecular genetics. Working with genetic
counselors to facilitate family interactions would also
be a critical foundational exposure. Finally, there
should be formal training to develop an informed and
critical approach to interpreting genetic testing
results, including exposure to key gene variant ana-
lytic platforms and training on the use of publicly
available databases of human genomic variation.
Associated imaging for diagnosis and risk stratiﬁca-
tion of genetic conditions for key diseases also would
be an important cornerstone.
In conclusion, cardiovascular genetics is rapidly
emerging as a new paradigm for diagnosing and
managing cardiovascular diseases. Its relevance to
the practice of clinical medicine has transcended the
laboratory, and clinicians now require expertise in
this ﬁeld to make appropriate, informed patient
care decisions. Training fellows in cardiovascular
genetics will be critical to ensure that the cardio-
vascular community is able to provide efﬁcient,
high-quality, personalized care for the next genera-
tion of patients.
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